SecBot SecBot
PRESS-RELEASE ·Filed Mar 11, 2026

KMDA

Kamada Ltd.
BULLISH
Impact 8/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The combination of accelerating profitability, strong cash flow, affirmed growth guidance, and new dividend policy suggests Kamada is transitioning to a more mature, cash-generative biopharma profile. The stock may re-rate if 2026 execution matches guidance, especially given the low market cap (~$515M). Monitor M&A activity and plasma collection ramp-up as future catalysts.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$8.30
T+0 close · Mar 11, 2026 · via day close
Latest settled
−10.95%
T+60 · $7.39
Vs SPY
−22.47%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 11 $8.30entry
  2. T+1 · 8mo ago +1.64%α +3.12% · $8.43
  3. T+5 · 8mo ago +0.47%α +2.66% · $8.34
  4. T+20 · 7mo ago +2.55%α +2.02% · $8.51
  5. T+60 · 6mo ago −10.95%α −22.47% · $7.39
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Kamada Ltd. reported strong 2025 full-year results with revenue of $180.5 million (up 12% YoY), adjusted EBITDA of $42.0 million (up 23% YoY), and net income of $20.2 million (up 40% YoY). The company affirmed its 2026 guidance of $200M–$205M in revenue and $50M–$53M in adjusted EBITDA, while declaring its first annual cash dividend of $0.25 per share ($14.4M total).

Key Financial Metrics

Revenue
$180.5M
+12.0% YoY
EPS
$0.35
Guidance
$200M-$205M
maintained
Deal Value
$14.0M

Key Facts

  • 2025 revenue: $180.5M (+12% YoY), driven by VARIZIG®, KEDRAB®, KAMRAB®, and GLASSIA® sales
  • 2025 adjusted EBITDA: $42.0M (+23% YoY); net income: $20.2M (+40% YoY)
  • Affirmed 2026 guidance: $200M–$205M revenue (+13% mid-point growth), $50M–$53M adjusted EBITDA (+23% mid-point growth)
  • Generated $25.5M in operating cash flow; ended year with $75.5M in cash
  • Declared first annual dividend of $0.25 per share ($14.4M total), payable April 6, 2026
  • Secured $10M–$14M Canadian Blood Services tender extension through Q1-2028

Financial Impact

Revenue and earnings growth accelerating, with 2026 guidance implying sustained double-digit growth. Dividend adds shareholder return dimension.

revenueepsebitdacash_flowdividend

Risk Factors

  • Fourth-quarter deceleration: Q4 revenue up 15% but net income and adjusted EBITDA declined YoY
  • Operating cash flow dropped to $25.5M in 2025 from $47.6M in 2024 due to working capital build
  • Discontinuation of Phase 3 Inhaled AAT trial removes a key pipeline catalyst

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3253639

Track record

25 reports on KMDA

Performance horizon

7 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +16.13% at T+20 after the Aug 12, 2026 report. 9 of 10 went positive at some point.

Filters
  1. Nov 9, 20267d ago 6-K Bullish 6/10 No price data
  2. Nov 9, 20267d ago Press Release Bullish 6/10 Entry $7.71 to $8.11 Now $8.11 +5.19% ▲ +5.19% +6.88% vs SPY
  3. Nov 2, 202614d ago 6-K Neutral 2/10 Entry $7.36 to $7.71 Now $8.11 +10.19% ▲ +4.76% +4.68% vs SPY
  4. Oct 6, 20265w ago 6-K Neutral 4/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
  5. Oct 6, 20265w ago Press Release Bullish 6/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
  6. Oct 5, 20266w ago 6-K Neutral 2/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
  7. Sep 17, 20268w ago 6-K Bullish 6/10 Entry $8.67 to $8.83 Now $8.11 −6.46% ▲ +1.85% +1.24% vs SPY
  8. Sep 16, 20268w ago EFFECT Neutral 3/10 Entry $8.19 to $8.77 Now $8.11 −0.98% ▲ +7.08% +4.52% vs SPY
  9. Sep 10, 20269w ago 6-K Neutral 2/10 Entry $7.99 to $8.67 Now $8.11 +1.50% ▲ +8.51% +9.01% vs SPY
  10. Sep 3, 202610w ago Press Release Neutral 2/10 Entry $8.54 to $8.31 Now $8.11 −5.04% ▼ −2.69% −1.48% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 9h 25m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 11, 2026